Intra-Cellular Therapies, Inc. (ITCI)

68,80 -1,54 (-2,19%) Alla chiusura: 04:00PM EDT

Intra-Cellular Therapies, Inc.

430 East 29th Street
New York, NY 10016
United States
646 440 9333
https://www.intracellulartherapies.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 610

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Sharon Mates Ph.D.	Co-Founder, Chairman & CEO	2,34M	2,16M	1953
Mr. Michael I. Halstead J.D.	President	1,03M	2,02M	1973
Dr. Suresh K. Durgam M.D.	Executive VP & Chief Medical Officer	1,01M	N/D	1969
Mr. Mark Neumann	EVP & Chief Commercial Officer	1,04M	3,08M	1963
Dr. Robert E. Davis Ph.D.	Senior VP & Chief Scientific Officer	646,12k	N/D	1951
Mr. Juan Fernando Sanchez	Vice President of Corporate Communications & Investor Relations	296,75k	N/D	1971
Ms. Karen Patruno Sheehy Esq.	Senior VP & Chief Compliance Officer	N/D	N/D	1962
John P. Condon	Senior Vice President, General Counsel & Secretary	N/D	N/D	N/D
Dr. Michael Olchaskey	Senior VP & Head of Regulatory Affairs	N/D	N/D	N/D
Mr. John A. Bardi	Senior VP of Market Access, Policy & Government Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Intra-Cellular Therapies, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.